About
Engineered Cytokines
Areas of Focus
Categories
Biologics & BiopharmaceuticalBiotech
Team (6)
Antoni Ribas
Antoni Ribas, M.D., Ph.D.
Synthekine
team_member
Casey Weaver
Casey Weaver, M.D.
Synthekine
team_member
Christopher A
Christopher A. Hunter, Ph.D.
Synthekine
team_member
Christopher Garcia
Christopher Garcia, Ph.D.
Synthekine
team_member
Nils Lonberg
Nils Lonberg, Ph.D.
Synthekine
team_member
Rob Kastelein
Rob Kastelein, Ph.D.
Synthekine
team_member
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
3
As Collaborator
0
Total Enrollment
286
By Phase
PHASE1: 3
By Status
RECRUITING: 2ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
Today
Hover over trial bars to see details
Recent Trials
NCT06544330Lead Sponsor
A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease
PHASE1Recruiting
48 participants
Started: Apr 29, 2025 · Completed: Apr 30, 2041
NCT05665062Lead Sponsor
Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies
PHASE1Active, not recruiting
36 participants
Started: Apr 23, 2023 · Completed: Nov 30, 2026
NCT05098132Lead Sponsor
STK-012 Monotherapy and in Combination Therapy in Patients With Solid Tumors
PHASE1Recruiting
202 participants
Started: Jan 25, 2022 · Completed: Oct 31, 2027
Locations (1)
Headquarters
Menlo Park, CA, United States
Map
Loading map...